Published in AIDS on July 13, 2006
Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. Trop Med Int Health (2008) 5.32
Adult mortality and antiretroviral treatment roll-out in rural KwaZulu-Natal, South Africa. Bull World Health Organ (2009) 3.77
Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings. Clin Infect Dis (2009) 3.76
Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared. PLoS Med (2008) 3.56
Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries. J Acquir Immune Defic Syndr (2014) 2.79
Modifications of a large HIV prevention clinical trial to fit changing realities: a case study of the Breastfeeding, Antiretroviral, and Nutrition (BAN) protocol in Lilongwe, Malawi. Contemp Clin Trials (2008) 2.35
Metabolic function and the prevalence of lipodystrophy in a population of HIV-infected African subjects receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 1.70
Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial. J Acquir Immune Defic Syndr (2009) 1.45
The impact of monitoring HIV patients prior to treatment in resource-poor settings: insights from mathematical modelling. PLoS Med (2008) 1.32
CD4 immunophenotyping in HIV infection. Nat Rev Microbiol (2008) 1.27
Immunologic and virologic failure after first-line NNRTI-based antiretroviral therapy in Thai HIV-infected children. AIDS Res Ther (2011) 1.22
National adult antiretroviral therapy guidelines in South Africa: concordance with 2003 WHO guidelines? AIDS (2007) 1.09
The effects of exercise training on quality of life in HAART-treated HIV-positive Rwandan subjects with body fat redistribution. Qual Life Res (2008) 1.07
A longitudinal study of stavudine-associated toxicities in a large cohort of South African HIV infected subjects. BMC Infect Dis (2011) 1.07
Assessment of quality of life in HAART-treated HIV-positive subjects with body fat redistribution in Rwanda. AIDS Res Ther (2007) 0.98
Estimating the resources required in the roll-out of universal access to antiretroviral treatment in Zimbabwe. Sex Transm Infect (2011) 0.97
Safety, Tolerability, and Efficacy of Second-Line Generic Protease Inhibitor Containing HAART after First-Line Failure among South Indian HIV-Infected Patients. J Int Assoc Physicians AIDS Care (Chic) (2011) 0.85
Adult combination antiretroviral therapy in sub-Saharan Africa: lessons from Botswana and future challenges. HIV Ther (2009) 0.83
Cost-effectiveness of early initiation of first-line combination antiretroviral therapy in Uganda. BMC Public Health (2012) 0.83
Cytotoxicological analysis of a gp120 binding aptamer with cross-clade human immunodeficiency virus type 1 entry inhibition properties: comparison to conventional antiretrovirals. Antimicrob Agents Chemother (2009) 0.82
Poor efficacy and tolerability of stavudine, didanosine, and efavirenz-based regimen in treatment-naive patients in Senegal. MedGenMed (2007) 0.79
The impact of antiretroviral therapy on population-level virulence evolution of HIV-1. J R Soc Interface (2015) 0.79
Effect modification by sex and baseline CD4+ cell count among adults receiving combination antiretroviral therapy in Botswana: results from a clinical trial. AIDS Res Hum Retroviruses (2012) 0.78
Clinical Analysis of Five Cases of AIDS-related Non-Hodgkin Lymphoma. Pak J Med Sci (2017) 0.75
Poor Efficacy and Tolerability of Stavudine, Didanosine, and Efavirenz-based Regimen in Treatment-Naive Patients in Senegal. J Int AIDS Soc (2007) 0.75
Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet (2008) 36.01
The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet (2006) 11.06
Prevention of mother-to-child transmission of HIV and the health-related Millennium Development Goals: time for a public health approach. Lancet (2011) 5.00
Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS (2002) 4.42
Investment in HIV/AIDS programs: does it help strengthen health systems in developing countries? Global Health (2008) 4.10
The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther (2008) 4.00
Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS (2002) 3.99
Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther (2008) 3.35
To retain or remove user fees?: reflections on the current debate in low- and middle-income countries. Appl Health Econ Health Policy (2006) 3.06
World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites. Antivir Ther (2008) 3.02
Cost-effectiveness of highly active antiretroviral therapy in South Africa. PLoS Med (2005) 3.01
Non-typhoidal salmonella bacteraemia among HIV-infected Malawian adults: high mortality and frequent recrudescence. AIDS (2002) 2.83
Malaria attributable to the HIV-1 epidemic, sub-Saharan Africa. Emerg Infect Dis (2005) 2.80
Antiretroviral therapy in prevention of HIV and TB: update on current research efforts. Curr HIV Res (2011) 2.45
Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050. PLoS One (2012) 2.39
The global fight against HIV/AIDS, tuberculosis, and malaria: current status and future perspectives. Am J Clin Pathol (2009) 2.34
Trends in retention on antiretroviral therapy in national programs in low-income and middle-income countries. J Acquir Immune Defic Syndr (2010) 2.33
A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med (2010) 2.30
Monitoring the scale-up of antiretroviral therapy programmes: methods to estimate coverage. Bull World Health Organ (2006) 2.20
What strategies to boost production of affordable fixed-dose anti-retroviral drug combinations for children in the developing world? Curr HIV Res (2007) 2.12
HIV infection as a cofactor for severe falciparum malaria in adults living in a region of unstable malaria transmission in South Africa. AIDS (2004) 2.12
Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis (2005) 2.07
Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial. Antivir Ther (2006) 2.02
Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy. Clin Infect Dis (2008) 1.98
Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first- and second-line regimens. AIDS (2007) 1.94
Implementation of co-trimoxazole prophylaxis and isoniazid preventive therapy for people living with HIV. Bull World Health Organ (2009) 1.91
Evaluation of filter paper transfer of whole-blood and plasma samples for quantifying HIV RNA in subjects on antiretroviral therapy in Uganda. J Acquir Immune Defic Syndr (2007) 1.89
Effectiveness of cotrimoxazole prophylaxis on mortality in adults with tuberculosis in rural South Africa. AIDS (2005) 1.88
Highly active antiretroviral treatment as prevention of HIV transmission: review of scientific evidence and update. Curr Opin HIV AIDS (2010) 1.83
International recommendations on antiretroviral drugs for treatment of HIV-infected women and prevention of mother-to-child HIV transmission in resource-limited settings: 2006 update. Am J Obstet Gynecol (2007) 1.82
Pneumococcal disease in HIV-infected Malawian adults: acute mortality and long-term survival. AIDS (2002) 1.79
Treatment of chronic hepatitis B virus infection in resource-constrained settings: expert panel consensus. Liver Int (2011) 1.75
Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. AIDS (2002) 1.74
Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. AIDS (2014) 1.67
Mother-to-child transmission of human herpesvirus-8 in South Africa. J Infect Dis (2004) 1.64
New WHO HIV treatment and prevention guidelines. Lancet (2009) 1.59
Derivation of parameters used in Spectrum for eligibility for antiretroviral therapy and survival on antiretroviral therapy. Sex Transm Infect (2010) 1.59
Can antiretroviral therapy eliminate HIV transmission? Lancet (2008) 1.53
Highly active antiretroviral treatment for the prevention of HIV transmission. J Int AIDS Soc (2010) 1.51
Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin. J Acquir Immune Defic Syndr (2005) 1.50
Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. AIDS (2013) 1.49
Clinical characteristics of IRIS syndrome in patients with HIV and tuberculosis. Antivir Ther (2005) 1.48
Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial. PLoS Med (2012) 1.44
Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study. J Acquir Immune Defic Syndr (2004) 1.42
Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. AIDS (2002) 1.40
Global progress in PMTCT and paediatric HIV care and treatment in low- and middle-income countries in 2004-2005. Reprod Health Matters (2007) 1.37
The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen. Clin Infect Dis (2008) 1.36
World Health Organization/HIVResNet Drug Resistance Laboratory Strategy. Antivir Ther (2008) 1.36
Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus Abacavir. J Infect Dis (2010) 1.36
A meta-analysis of transient elastography for the detection of hepatic fibrosis. J Clin Gastroenterol (2010) 1.34
Cost effectiveness analysis of clinically driven versus routine laboratory monitoring of antiretroviral therapy in Uganda and Zimbabwe. PLoS One (2012) 1.33
A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy. Ann Intern Med (2005) 1.31
When should HAART be initiated in pregnancy to achieve an undetectable HIV viral load by delivery? AIDS (2012) 1.29
Childhood malaria in a region of unstable transmission and high human immunodeficiency virus prevalence. Pediatr Infect Dis J (2003) 1.28
The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001. AIDS (2004) 1.27
Virologic rebound on HAART in the context of low treatment adherence is associated with a low prevalence of antiretroviral drug resistance. J Acquir Immune Defic Syndr (2002) 1.24
The role for government health centers in provision of same-day voluntary HIV counseling and testing in Kenya. J Acquir Immune Defic Syndr (2005) 1.23
Missed opportunities for early infant HIV diagnosis: results of a national study in South Africa. J Acquir Immune Defic Syndr (2015) 1.22
Estimation of antiretroviral therapy coverage: methodology and trends. Curr Opin HIV AIDS (2010) 1.21
Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients. Antivir Ther (2007) 1.20
Estimating glomerular filtration rate in HIV-infected adults in Africa: comparison of Cockcroft-Gault and Modification of Diet in Renal Disease formulae. Antivir Ther (2008) 1.20
HIV testing in non-traditional settings--the HINTS study: a multi-centre observational study of feasibility and acceptability. PLoS One (2012) 1.18
HIV and tuberculosis: partners in crime. Indian J Dermatol Venereol Leprol (2006) 1.15
Utilization patterns and projected demand of antiretroviral drugs in low- and middle-income countries. AIDS Res Treat (2011) 1.15
A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma. AIDS (2003) 1.15
The 2013 WHO guidelines for antiretroviral therapy: evidence-based recommendations to face new epidemic realities. Curr Opin HIV AIDS (2013) 1.14
Antiretroviral treatment regimens and immune parameters in the prevention of systemic AIDS-related non-Hodgkin's lymphoma. J Clin Oncol (2004) 1.14
High rate of HIV resuppression after viral failure on first-line antiretroviral therapy in the absence of switch to second-line therapy. Clin Infect Dis (2013) 1.12
Conjugate pneumococcal vaccine in HIV-infected Ugandans and the effect of past receipt of polysaccharide vaccine. J Infect Dis (2005) 1.10
The cost-effectiveness of early access to HIV services and starting cART in the UK 1996-2008. PLoS One (2011) 1.09
Cytokine responses and progression to active tuberculosis in HIV-1-infected Ugandans: a prospective study. Trans R Soc Trop Med Hyg (2004) 1.09
Discontinuation of Atripla as first-line therapy in HIV-1 infected individuals. AIDS (2012) 1.09
The Lablite project: a cross-sectional mapping survey of decentralized HIV service provision in Malawi, Uganda and Zimbabwe. BMC Health Serv Res (2014) 1.08
Mortality in the year following antiretroviral therapy initiation in HIV-infected adults and children in Uganda and Zimbabwe. Clin Infect Dis (2012) 1.07
Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience. AIDS (2007) 1.06
Comparative efficacy of Lamivudine and emtricitabine: a systematic review and meta-analysis of randomized trials. PLoS One (2013) 1.05
Changes in antiretroviral therapy guidelines: implications for public health policy and public purses. Sex Transm Infect (2010) 1.04
Long-term care of AIDS and non-communicable diseases. Lancet (2011) 1.04
Costs of hospital care for HIV-positive and HIV-negative patients at Kenyatta National Hospital, Nairobi, Kenya. AIDS (2002) 1.03
23-Valent pneumococcal polysaccharide vaccine in HIV-infected Ugandan adults: 6-year follow-up of a clinical trial cohort. AIDS (2004) 1.03
The risks and incidence of K65R and L74V mutations and subsequent virologic responses. Clin Infect Dis (2008) 1.03
Beyond indicators: advances in global HIV monitoring and evaluation during the PEPFAR era. J Acquir Immune Defic Syndr (2012) 1.02
Evolution of drug resistance during 48 weeks of zidovudine/lamivudine/tenofovir in the absence of real-time viral load monitoring. J Acquir Immune Defic Syndr (2010) 1.01